- Group B streptococcus (GBS) testing with PCR in Labor and Delivery (L&D) improves detection and treatment rates.
Why this matters
- Prevention of early-onset GBS disease in newborns currently relies on culture testing at 35-37 weeks gestation and intrapartum antibiotics.
- Molecular screening allows for point-of-care testing.
- Positive screening rates were higher with PCR (14.5% vs 12.2%; P<.001>
- No difference in women receiving antibiotics with different modes of detection.
- More women underwent GBS testing during the intervention (99.9% vs 96.2%; P<.001>
- In both periods, approximately 50% of treated women received at least 2 doses of penicillin G.
- Early-onset GBS disease declined with the intervention (64% decline vs 60% decline).
- Cost decreased with PCR testing (average cost of delivery $2691 vs $2381); the additional costs of the PCR test were offset by decrease of early-onset GBS disease treatment costs.
- Single-institution, before/after uncontrolled study.
- Intervention was intrapartum GBS screening using PCR for term deliveries, implemented in 2010.
- Outcomes studied before intervention (GBS culture at 35-37 weeks of gestation; n=11,226) and after intervention (n=18,835) compared.
- Funding: None disclosed.
- No control group.
- Results may not be generalizable to other populations.